Knight Therapeutics Stock Market Value

KHTRF Stock  USD 3.73  0.04  1.08%   
Knight Therapeutics' market value is the price at which a share of Knight Therapeutics trades on a public exchange. It measures the collective expectations of Knight Therapeutics investors about its performance. Knight Therapeutics is trading at 3.73 as of the 23rd of November 2024. This is a 1.08 percent increase since the beginning of the trading day. The stock's lowest day price was 3.73.
With this module, you can estimate the performance of a buy and hold strategy of Knight Therapeutics and determine expected loss or profit from investing in Knight Therapeutics over a given investment horizon. Check out Knight Therapeutics Correlation, Knight Therapeutics Volatility and Knight Therapeutics Alpha and Beta module to complement your research on Knight Therapeutics.
Symbol

Please note, there is a significant difference between Knight Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Knight Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Knight Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Knight Therapeutics 'What if' Analysis

In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Knight Therapeutics' pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Knight Therapeutics.
0.00
10/24/2024
No Change 0.00  0.0 
In 31 days
11/23/2024
0.00
If you would invest  0.00  in Knight Therapeutics on October 24, 2024 and sell it all today you would earn a total of 0.00 from holding Knight Therapeutics or generate 0.0% return on investment in Knight Therapeutics over 30 days. Knight Therapeutics is related to or competes with Rezolute, Tempest Therapeutics, Forte Biosciences, Dyadic International, DiaMedica Therapeutics, Silo Pharma, and Molecular Partners. Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, an... More

Knight Therapeutics Upside/Downside Indicators

Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Knight Therapeutics' pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Knight Therapeutics upside and downside potential and time the market with a certain degree of confidence.

Knight Therapeutics Market Risk Indicators

Today, many novice investors tend to focus exclusively on investment returns with little concern for Knight Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Knight Therapeutics' standard deviation. In reality, there are many statistical measures that can use Knight Therapeutics historical prices to predict the future Knight Therapeutics' volatility.
Hype
Prediction
LowEstimatedHigh
2.163.735.30
Details
Intrinsic
Valuation
LowRealHigh
1.923.495.06
Details
Naive
Forecast
LowNextHigh
2.103.675.24
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
3.683.723.75
Details

Knight Therapeutics Backtested Returns

Knight Therapeutics has Sharpe Ratio of -0.11, which conveys that the firm had a -0.11% return per unit of risk over the last 3 months. Knight Therapeutics exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please verify Knight Therapeutics' Mean Deviation of 0.7352, standard deviation of 1.59, and Risk Adjusted Performance of (0.06) to check out the risk estimate we provide. The company secures a Beta (Market Risk) of -0.0609, which conveys not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Knight Therapeutics are expected to decrease at a much lower rate. During the bear market, Knight Therapeutics is likely to outperform the market. At this point, Knight Therapeutics has a negative expected return of -0.18%. Please make sure to verify Knight Therapeutics' value at risk, as well as the relationship between the daily balance of power and price action indicator , to decide if Knight Therapeutics performance from the past will be repeated at some point in the near future.

Auto-correlation

    
  -0.18  

Insignificant reverse predictability

Knight Therapeutics has insignificant reverse predictability. Overlapping area represents the amount of predictability between Knight Therapeutics time series from 24th of October 2024 to 8th of November 2024 and 8th of November 2024 to 23rd of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Knight Therapeutics price movement. The serial correlation of -0.18 indicates that over 18.0% of current Knight Therapeutics price fluctuation can be explain by its past prices.
Correlation Coefficient-0.18
Spearman Rank Test0.29
Residual Average0.0
Price Variance0.0

Knight Therapeutics lagged returns against current returns

Autocorrelation, which is Knight Therapeutics pink sheet's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Knight Therapeutics' pink sheet expected returns. We can calculate the autocorrelation of Knight Therapeutics returns to help us make a trade decision. For example, suppose you find that Knight Therapeutics has exhibited high autocorrelation historically, and you observe that the pink sheet is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
   Current and Lagged Values   
       Timeline  

Knight Therapeutics regressed lagged prices vs. current prices

Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Knight Therapeutics pink sheet is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Knight Therapeutics pink sheet is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Knight Therapeutics pink sheet over time.
   Current vs Lagged Prices   
       Timeline  

Knight Therapeutics Lagged Returns

When evaluating Knight Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Knight Therapeutics pink sheet have on its future price. Knight Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Knight Therapeutics autocorrelation shows the relationship between Knight Therapeutics pink sheet current value and its past values and can show if there is a momentum factor associated with investing in Knight Therapeutics.
   Regressed Prices   
       Timeline  

Currently Active Assets on Macroaxis

Other Information on Investing in Knight Pink Sheet

Knight Therapeutics financial ratios help investors to determine whether Knight Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Knight with respect to the benefits of owning Knight Therapeutics security.